Guided Therapeutics (GTHP) & Its Peers Financial Contrast

Guided Therapeutics (OTCMKTS:GTHP) is one of 78 public companies in the “Electromedical equipment” industry, but how does it compare to its peers? We will compare Guided Therapeutics to related businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, earnings, valuation and dividends.

Profitability

This table compares Guided Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-299.08%	-83.97%	-27.60%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Guided Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	287	825	2136	109	2.62

As a group, “Electromedical equipment” companies have a potential upside of 2,878.06%. Given Guided Therapeutics’ peers higher possible upside, analysts clearly believe Guided Therapeutics has less favorable growth aspects than its peers.

Insider and Institutional Ownership

9.7% of Guided Therapeutics shares are held by institutional investors. Comparatively, 44.3% of shares of all “Electromedical equipment” companies are held by institutional investors. 66.8% of Guided Therapeutics shares are held by insiders. Comparatively, 15.1% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Guided Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-5.33
Guided Therapeutics Competitors	$970.73 million	$79.50 million	9.84

Guided Therapeutics’ peers have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Guided Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ peers have a beta of 0.85, suggesting that their average share price is 15% less volatile than the S&P 500.

Summary

Guided Therapeutics peers beat Guided Therapeutics on 7 of the 10 factors compared.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.